SABS logo

SABSSAB Biotherapeutics Inc

$3.35
$0.07
(2.12%)
Today
Closed $3.38
$0.03
(0.89%)
After Hours
Updated: 04:52 PM EDT
EarningsAug 11
Mkt Cap$253.1M
Vol239,804.00
News
all
press releases
MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak
The HHS confirmed that one American passenger evacuated from the MV Hondius cruise ship tested mildly positive for the Andes strain of hantavirus.
Stocktwits
News Placeholder
More News
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of "Moderate Buy" by Brokerages
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a buy reco...
MarketBeat
News Placeholder
SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday
SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...
MarketBeat
News Placeholder
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8%
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totaling 3,000,764 shares, an increase of 19.8...
MarketBeat
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports...
MarketBeat
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Rodman & Renshaw
Rodman & Renshaw initiated coverage on SAB Biotherapeutics in a report on Thursday. They issued a "buy" rating and a $13.00 target price on the stock...
MarketBeat
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a large increase in short interest in March. As of March 13th, there was short interest totaling 1,953,472 shares, an increase of 21.1% from the February 26th total of 1,613,558 shares. Based on an average daily volume of 918,838...
MarketBeat
News Placeholder
SAB Biotherapeutics (SABS) to Release Earnings on Friday
SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q4 2025 earnings before the market opens on Friday, March 27. (View Earnings Report at...
MarketBeat
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat
News Placeholder
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS
Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.